Skip to content
OpenCapital
Get started

Outlook Therapeutics, Inc. OTLK Q4 2024 Annual earnings

Reported February 14, 2025 · Before market open

Diluted EPS-$0.89Miss by $0.04
Revenue estimate$702.6K
EPS estimate-$0.85

Next report

Aug 13, 2026 (In 3 weeks)
Revenue estimate$4.8M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$128.0KMiss by $4.3MQ4 2025-$1.2MMiss by $4.4MQ3 2025-$91.8KMiss by $5.9MQ2 2025$1.5MMiss by $4.3M

Diluted EPS

Q1 2026-$0.16Miss by $0.04Q4 2025-$0.22Miss by $0.05Q3 2025-$0.22Beat by $0.04Q2 2025-$0.44Miss by $0.02Q1 2025-$0.40Beat by $0.15
Q4 2024-$0.89Miss by $0.04

Ask the moment Outlook Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Outlook Therapeutics, Inc. report Q4 2024 earnings?
Outlook Therapeutics, Inc. (OTLK) reported Q4 2024 earnings on February 14, 2025 before market open.
What were Outlook Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Outlook Therapeutics, Inc. reported diluted EPS of $-0.89 for Q4 2024.
Did Outlook Therapeutics, Inc. beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.85 by $0.04.
Where can I find Outlook Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K/A periodic report (0001558370-25-000366) directly on SEC EDGAR. The filing index links above go to sec.gov.